REGISTER TODAY FOR THE 10TH INTERNATIONAL MPN PATIENT SYMPOSIUM IN NEW YORK CITY
The 10th International Patient Symposium on Myeloproliferative Neoplasms, presented by the Cancer Research & Treatment Fund (CR&T), will be held on Wednesday, October 23 at Weill Cornell Medicine in New York City. Patients and their families who attend this full-day event will learn about the latest advances in research developments and treatment, and participate in disease-specific Q&A sessions. This is a unique opportunity to engage with distinguished MPN researchers and physicians from the world’s leading cancer centers.
Spaces are limited. For details and to register online, click here, or call CR&T at 212-288-6604.
September 6, 2019 – 5th Annual Women & MPN Conference
November 8, 2019 – Brisbane, Australia
Registration opens soon!
MPN Advocacy & Education International Calendar of Events
MPN Quality of Life Study Group Website
The Myeloproliferative Neoplasm Quality of Life Study Group, headed by Dr. Ruben Mesa of the Mays Cancer Center, is a collaboration amongst leading MPN physicians and researchers from some of the most prestigious institutions in the world, including the Mays Cancer Center at UT Health San Antonio MD Anderson, Arizona State University, University of Arizona, University of California Irvine, and the Mayo Clinic.
Nominate your Hero today
Since 2013, the MPN Heroes Recognition Program has recognized the people and organizations that have dedicated themselves to improving the lives of people with MPNs. The program focuses on the three “classical” MPNs—or what are known as Philadelphia chromosome–negative MPNs.
2019 marks the seventh anniversary of the MPN Heroes Recognition Program, sponsored by Incyte Corporation and CURE magazine. Our goal is to create as many opportunities as possible for people with MPNs to be heard and to be supported, so more solutions and treatment options will emerge.
Created in the spirit of fostering community, the program recognizes patients, Healthcare Professionals, caregivers, advocates, and organizations that contribute to bringing understanding, compassion, and strength to the MPN community.
UT Health Cancer Center announces new director
Dr. Mesa is relocating to UT Health San Antonio Cancer Center, TX
5 year Results from the Phase 3 Study of Jakafi
Living with MPNs Survey
A 30-minute survey for patients with myeloproliferative neoplasms (MPNs). A research study (sponsored by Incyte Corporation) is being conducted to learn more about the impact of MPNs on patients’ lives. Incyte is seeking patients aged 18 to 70 with MF, PV or ET to participate in a one-time, 30-minute online survey about how your condition has affected your work, finances, and quality of life. If you are eligible and complete the survey, you will be compensated.For more information, please visit https://www.surveymonkey.com/r/VXTHC37
FDA approval of Jakafi (Ruxolitnib) for the treatment of Polycythemia Vera
National Organization of Rare Diseases
Stories about 3 patients (Antje with ET, Annette with PV and Bill with MF) on the NORD website:
The MPD Research Consortium is a National Cancer Institute supported project involving 50 International MPN Centers in the United States, Canada, Europe and Israel. It is a resource for both patients and physicians focusing on advancing the science and therapy of myeloproliferative neoplasms
Are You a Vietnam Veteran?
Were you exposed to Agent Orange? Do You Have Myelofibrosis (MF), Polycythemia Vera (PV) or Essential Thrombocythemia (ET)?
MPN Advocacy and Education International is conducting a survey of Vietnam Veterans to determine how many were exposed to Agent Orange and now have a diagnosis of Myelofibrosis, Polycythemia Vera, or Essential Thrombocythemia (Myeloproliferative Neoplasms- MPNs. This information will be collected in an attempt to add myeloproliferative neoplasms to the US Department of Veterans Affairs ‘presumptive’ list of conditions resulting from exposure to Agent Orange/dioxin during the Vietnam War and could create a resource for assistance with treatments and compensation.
This is our first step in what could allow for further research into the link between myeloprliferative neoplasms and exposure to Agent Orange/dioxin.
Please contact Ann Brazeau: